Tag: #Manufacturing
-
BREWERY SECTOR BOUNCES BACK — BUT NEW COST RISKS LOOM
Nigeria’s beer industry is back in profit after years of losses — but rising costs and new taxes could spoil the party. Lagos, April 16, 2026 — Nigeria’s brewed products sector returned to profitability in 2025 after years of losses, Nigerian Breweries Plc has said, even as consumers continue to feel the pinch of inflation.…
-
COMPANY INCOME TAX DROPS TO ₦1.49TRN IN Q4 2025 — NBS
Nigeria’s Q4 2025 CIT sees sharp quarterly decline but posts modest annual growth, with financial, manufacturing, and mining sectors leading contributions. The National Bureau of Statistics (NBS) reports that Nigeria collected ₦1.49 trillion in Company Income Tax (CIT) in Q4 2025, down 49.81% from ₦2.96 trillion in Q3. Domestic CIT contributed ₦819.83 billion, while foreign…
-
LAFARGE AFRICA SMASHES N1TRN REVENUE MARK, PROFITS SOAR 173%
Strong sales, plant efficiency and cost discipline power a record-breaking 2025. Lafarge Africa Plc has crossed a major financial milestone, posting N1.07 trillion in net sales for 2025 — a 53% jump from N696.76 billion recorded in 2024. In its audited results filed with the Nigerian Exchange Limited, the cement giant reported explosive profit growth…
-
WELDING POWERS NIGERIA’S INFRASTRUCTURE AND INDUSTRIAL GROWTH – NIW
From roads and refineries to telecom masts and farms, experts say welding is the backbone of development. The National Institute of Welding (NIW) has called on the Federal Government to step up investment in welding technology and skills, describing the profession as critical to Nigeria’s infrastructure and industrial expansion. Speaking in Lagos, NIW President Dr.…
-
U.S. DELAYS TRUMP’S PHARMA TARIFFS, SHIFTS FOCUS TO PRESSURING COMPANIES
Pharma import tariffs postponed as U.S. aims to push manufacturers to build locally or cut prices. The Trump administration has postponed the planned 100% tariffs on branded pharmaceutical imports set for October 1. Instead, officials will prepare tariffs targeting companies that refuse to relocate production to the U.S. or lower drug prices. Originally, firms could…
